Keyphrases
Breast Cancer
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Normal Breast
100%
Advanced Breast Cancer
100%
Capecitabine Monotherapy
100%
Capecitabine
75%
Median Progression-free Survival
75%
Confidence Interval
50%
Overall Survival
50%
Progression-free Survival
50%
Survival Median
50%
Female Patients
25%
Inclusion Criteria
25%
Targeted Therapy
25%
Estrogen Receptor-positive
25%
Median Overall Survival
25%
Estrogen Receptor-negative
25%
Human Epidermal Growth Factor Receptor
25%
Oncology Department
25%
Alternative Chemotherapy
25%
Medicine and Dentistry
Retrospective Study
100%
Monotherapy
100%
Breast Cancer
100%
Capecitabine
100%
Progression Free Survival
83%
Overall Survival
50%
Estrogen Receptor
33%
Disease
16%
Oncology
16%
Targeted Therapy
16%
Epidermal Growth Factor Receptor
16%
Gamma Urogastrone
16%
Pharmacology, Toxicology and Pharmaceutical Science
Retrospective Study
100%
Breast Cancer
100%
Monotherapy
100%
Capecitabine
100%
Progression Free Survival
83%
Overall Survival
50%
Estrogen Receptor
33%
Disease
16%
Chemotherapy
16%
Epidermal Growth Factor Receptor
16%
Gamma Urogastrone
16%